|
| Investigators identified urokinase-type plasminogen activator receptor (uPAR) as a potential therapeutic target for diffuse-type gastric cancer.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using colorectal cancer patient-derived organoids, researchers showed that sublethal doses of chemotherapy did not select previously resistant tumor populations but induced a quiescent state specifically to TP53 wildtype cancer cells.
[Nature Communications] |
|
|
|
| Scientists identified co-ordinate epigenetic inactivation of two epithelial-specific transcription factors, Ets homologous factor (EHF) and caudal type homeobox 1 (CDX1), as a mechanism driving differentiation loss in colorectal cancers.
[Cell Death & Differentiation] |
|
|
|
| Analysis using high-throughput RNA-seq profile from The Cancer Genome Atlas found that the gene expression of Methyltransferase-like 3 was significantly upregulated among 20 N6-methyladenosine (m6A) binding proteins in colorectal cancer (CRC), which was also validated in CRC cancer tissues and cell lines.
[Cell Death & Disease] |
|
|
|
| Researchers showed that long-term and short-term cultures of colorectal cancers with microsatellite instability contained subpopulations of cells lacking histone deacetylase-2 (HDAC2).
[Cell Biology and Toxicology] |
|
|
|
| Scientists found that both phosphorylated CTD interacting factor 1 (PCIF1) expression and N6,2′-O-dimethyladenosine (m6Am) modification were significantly elevated in gastric cancer tissues.
[Cell Discovery] |
|
|
|
| The authors investigated the interplay with the metastasis driver S100 calcium-binding protein P (S100P) in colorectal cancer progression. Alterations in cell proliferation and motility were determined by functional in vitro assays.
[British Journal of Cancer] |
|
|
|
| Bioinformatic analysis, in vitro, and in vivo experiments revealed that aldehyde dehydrogenase 1 family member L1 (ALDH1L1) was a radiation-related gene, and a decrease in its expression induced radioresistance in colorectal cancer cells by inhibiting ROS-mediated apoptosis.
[British Journal of Cancer] |
|
|
|
| Cells grown in 3D cultures were sensitive to the oxidative phosphorylation inhibitor nitazoxanide, sorafenib, and regorafenib and resistant to other multikinase inhibitors and chemotherapeutic drugs.
[Scientific Reports] |
|
|
|
|
| Investigators focus on novel biomarkers that have emerged in recent years. They note that these serological biomarkers and microRNAs could potentially be used for disease management in IBD, thereby decreasing patient discomfort and morbidity.
[Medical Research Reviews] |
|
|
|
|
| Mersana Therapeutics, Inc. announced that the FDA has granted orphan drug designation to XMT-2056, the company’s lead Immunosynthen STING-agonist antibody-drug conjugate, for the treatment of gastric cancer.
[Mersana Therapeutics, Inc.] |
|
|
|
|
| November 1- 6, 2022
Virtual |
|
|
|
|
|
| | Weill Cornell Medicine – New York, New York, United States |
|
|
|
| | The Ohio State University – Columbus, Ohio, United States |
|
|
|
| | CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom |
|
|
|
|
| | Stanford University – Palo Alto, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
